Worth reading
81Important
Scored from 1 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
54.7
mg/dL (mean reduction in serum TG at week 4)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Factors Behind Changes in Business Performance
The clinical trial showed reductions in serum TG, increases in HDL-C and HDL-P, and improvement trends in liver fat content and body weight.
| Item | Details |
|---|---|
| Factors Behind Changes in Business Performance | The clinical trial showed reductions in serum TG, increases in HDL-C and HDL-P, and improvement trends in liver fat content and body weight. |
Items this document does not state (37)
Fiscal Period ClassificationAccounting standardsConsolidated / non-consolidatedPeriod CoveredNet SalesOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the MN-001 group, serum TG levels decreased by 30.96 mg/dL more than in the placebo group at week 4, while HDL-C and HDL-P increased significantly at week 24. Improvement trends were also observed in liver fat content and body weight.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.